ArticleJournal of gastrointestinal oncology2011
Nanovector-based therapies in advanced pancreatic cancer.
Article in Journal of gastrointestinal oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized Phase II Trial of Fluorouracil and Folinic Acid With or Without Liposomal Irinotecan (ONIVYDE) for Patients With Metastatic Biliary Tract Cancer Which Progressed Following Gemcitabine Plus Cisplatin
A Phase Ib/II Study of Ramucirumab (Cyramza®), Nal-IRI (ONIVYDE®) and Trifluridine/Tipiracil (Lonsurf®) in Second Line Metastatic Gastric Cancer (COOL Study).
Who cites it
11 citing papers in PubMed.
- Polyallylamine Hydrochloride-Modified Bovine Serum Albumin Nanoparticles Loaded with α-Solanine for Chemotherapy of Pancreatic Cancer.International journal of nanomedicine · 2025Article
- BPRDP056, a novel small molecule drug conjugate specifically targeting phosphatidylserine for cancer therapy.Translational oncology · 2021Article
- A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial.Therapeutic advances in medical oncology · 2020Article
- Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer.Clinical pharmacology and therapeutics · 2017Article
- A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors.BMC cancer · 2016Article
- Nanovectors for anti-cancer drug delivery in the treatment of advanced pancreatic adenocarcinoma.World journal of gastroenterology · 2016Review
- Onivyde for the therapy of multiple solid tumors.OncoTargets and therapy · 2016Review
- Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan.International journal of nanomedicine · 2016Review
- Targeted therapies for pancreatic adenocarcinoma: Where do we stand, how far can we go?World journal of gastrointestinal oncology · 2015Article
- Selection of pancreatic cancer cell-binding landscape phages and their use in development of anticancer nanomedicines.Protein engineering, design & selection : PEDS · 2014Article
- Pancreatic cancer: current standards, research updates and future directions.Journal of gastrointestinal oncology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic therapy for advanced pancreatic cancer has been largely disappointing owing to the unfavorable pharmacokinetic profile and poor penetration of current chemotherapeutic agents ,as well as the fragile patient population with compromised tolerance to toxic chemotherapies. Nanovectors can provide passive drug delivery through abnormal tumor neo-vasculature microanatomy or active targeting via binding to receptors or macromolecules associated with the tumor. In such a manner, nanovector-based therapy may not only modulate the pharmacokinetics and therapeutic index of chemotherapeutic agents but also provide new treatment options in patients with advanced pancreatic cancer. In this article, we present the rationale and currently available clinical results of nanovector-based therapies to highlight the potential use of this class of agent in patients with advanced pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.